A new drug called Eplontersen (Wainua) has recently been approved by the FDA for the treatment of polyneuropathy associated with hereditary transthyretin-mediated amyloidosis (ATTR) in adults. This approval comes as a significant breakthrough in the field of medicine, offering hope to the thousands of individuals affected by this condition.
Hereditary ATTR is a genetic disorder caused by a mutation in the TTR gene. This mutation leads to the accumulation of misfolded transthyretin protein, resulting in the formation of amyloid deposits in either the peripheral nerves (ATTR-PN) or the heart (ATTR cardiomyopathy). ATTR-PN, affecting approximately 30,000 to 40,000 people globally, poses significant challenges to patients’ quality of life.
Eplontersen is a ligand-conjugated antisense oligonucleotide drug designed to target and reduce the production of TTR protein. By inhibiting the production of this protein, Eplontersen effectively addresses both hereditary and non-hereditary forms of ATTR.
The efficacy of Eplontersen was evaluated in the open-label, single-group, phase III NEURO-TTRansform trial. The results of this trial demonstrated significant improvements in patients treated with Eplontersen, compared to a historical placebo cohort. These improvements included lower serum transthyretin concentration, reduced neuropathy impairment, and an enhanced quality of life.
During the study period of up to 66 weeks, adverse events that led to the discontinuation of the study drug occurred in 4% of the Eplontersen group and 3% of the placebo group. Furthermore, there were two deaths in the Eplontersen group, both consistent with known disease-related complications, while no deaths were reported in the placebo group. These findings underscore the importance of carefully monitoring patients for any potential adverse events.
Eplontersen marks the fourth drug to receive FDA approval for the treatment of ATTR-PN and is the second antisense oligonucleotide treatment to be approved. Unlike its predecessors, Eplontersen is unique in that it can be self-administered using an auto-injector, offering convenience and autonomy for patients.
One of the significant challenges faced by individuals with hereditary transthyretin-mediated amyloidosis, and other forms of amyloidosis, is the potential for misdiagnosis. The symptoms of this condition often resemble those of other diseases, making an accurate diagnosis a lengthy and arduous process. Timely and accurate diagnoses are not only crucial for patients but also for their families and loved ones. The approval of Eplontersen represents a major step forward in raising awareness and addressing the long-standing neglect of this condition.
As the benefits of Eplontersen continue to be recognized, ongoing research is being conducted to explore its potential in treating ATTR cardiomyopathy. The phase III CARDIO-TTRansform study aims to further evaluate the efficacy and safety of Eplontersen in managing this aspect of the condition.
The FDA approval of Eplontersen provides renewed hope for individuals suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis. This groundbreaking drug offers a new pathway towards improved quality of life for patients and their families, highlighting the importance of timely diagnosis and innovative treatments in addressing previously overlooked conditions.
Leave a Reply